Skip Nav Destination
Issues
1 February 2015
-
Cover Image
Cover Image
A complex network of hyaluronan (HA) and proteoglycans in the tumor microenvironment with high levels of HA (HAhigh) forms a physical barrier capable of inhibiting therapeutic monoclonal antibody (mAb) and immune cell access to tumor cells, resulting in a more aggressive tumor phenotype in several solid tumor types. Microscopic cell imaging shows that a physical barrier surrounding HAhigh tumor cell restricts human NK cells from accessing the tumor cell. These results demonstrate that HA depletion by PEGPH20 removes this barrier and allows increased mAb and immune cell access to the tumor cell, resulting in more efficient antibody-dependent cell-mediated cytotoxicity (ADCC)-dependent tumor cell killing. For details, see the article by Singha and colleagues on page 523. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Small Molecule Therapeutics
Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Lindsey N. Micel; John J. Tentler; Aik-Choon Tan; Heather M. Selby; Kelsey L. Brunkow; Kelli M. Robertson; S. Lindsey Davis; Peter J. Klauck; Todd M. Pitts; Esha Gangolli; Robyn Fabrey; Shawn M. O'Connell; Patrick W. Vincent; S. Gail Eckhardt
Identification of Novel Radiosensitizers in a High-Throughput, Cell-Based Screen for DSB Repair Inhibitors
Alexander G. Goglia; Robert Delsite; Antonio N. Luz; David Shahbazian; Ahmed F. Salem; Ranjini K. Sundaram; Jeanne Chiaravalli; Petrus J. Hendrikx; Jennifer A. Wilshire; Maria Jasin; Harriet M. Kluger; J. Fraser Glickman; Simon N. Powell; Ranjit S. Bindra
A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Kazuteru Fukasawa; Shigehide Kagaya; Sakiko Maruyama; Shunsuke Kuroiwa; Kuniko Masuda; Yoshio Kameyama; Yoshitaka Satoh; Yuichi Akatsu; Arihiro Tomura; Kiyohiro Nishikawa; Shigeo Horie; Yuh-ichiro Ichikawa
Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia
Santi Suryani; Lauryn S. Bracken; Richard C. Harvey; Keith C.S. Sia; Hernan Carol; I-Ming Chen; Kathryn Evans; Philipp A. Dietrich; Kathryn G. Roberts; Raushan T. Kurmasheva; Catherine A. Billups; Charles G. Mullighan; Cheryl L. Willman; Mignon L. Loh; Stephen P. Hunger; Peter J. Houghton; Malcolm A. Smith; Richard B. Lock
Author Choice
AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
Cong Li; Liqin Liu; Lingming Liang; Zhen Xia; Zhihong Li; Xianghong Wang; Lawrence R. McGee; Katie Newhall; Angus Sinclair; Alexander Kamb; Dineli Wickramasinghe; Kang Dai
The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET-Amplified Cancer
Coumaran Egile; Mireille Kenigsberg; Christine Delaisi; Françoise Bégassat; Véronique Do-Vale; Jessica Mestadier; Fabrice Bonche; Tsiala Bénard; Jean-Paul Nicolas; Sandrine Valence; Céline Lefranc; Elisa Francesconi; Christelle Castell; Anne-Marie Lefebvre; Conception Nemecek; Loreley Calvet; Hélène Goulaouic
The Use of Dipeptide Derivatives of 5-Aminolaevulinic Acid Promotes Their Entry to Tumor Cells and Improves Tumor Selectivity of Photodynamic Therapy
Gabriela Di Venosa; Pablo Vallecorsa; Francesca Giuntini; Leandro Mamone; Alcira Batlle; Silvia Vanzuli; Angeles Juarranz; Alexander J. MacRobert; Ian M. Eggleston; Adriana Casas
A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors
Kari L. Kendra; Ruth Plummer; Ravi Salgia; Mary E. R. O'Brien; Elaine M. Paul; A. Benjamin Suttle; Natalie Compton; Chun-Fang Xu; Lone H. Ottesen; Miguel A. Villalona-Calero
Large Molecule Therapeutics
Author Choice
Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models
Sheng-Bin Peng; Xiaoyi Zhang; Donald Paul; Lisa M. Kays; Wendy Gough; Julie Stewart; Mark T. Uhlik; Qi Chen; Yu-Hua Hui; Maciej J. Zamek-Gliszczynski; John A. Wijsman; Kelly M. Credille; Liang Zeng Yan
Cancer Biology and Signal Transduction
Author Choice
Tumor-Suppressor Role of Notch3 in Medullary Thyroid Carcinoma Revealed by Genetic and Pharmacological Induction
Renata Jaskula-Sztul; Jacob Eide; Sara Tesfazghi; Ajitha Dammalapati; April D. Harrison; Xiao-Min Yu; Casi Scheinebeck; Gabrielle Winston-McPherson; Kevin R. Kupcho; Matthew B. Robers; Amrit K. Hundal; Weiping Tang; Herbert Chen
Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
Remi Adelaiye; Eric Ciamporcero; Kiersten Marie Miles; Paula Sotomayor; Jonathan Bard; Maria Tsompana; Dylan Conroy; Li Shen; Swathi Ramakrishnan; Sheng-Yu Ku; Ashley Orillion; Joshua Prey; Gerald Fetterly; Michael Buck; Sreenivasulu Chintala; Georg A. Bjarnason; Roberto Pili
Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Yuji Sano; Eri Hashimoto; Noriaki Nakatani; Masaichi Abe; Yasuko Satoh; Kiyoaki Sakata; Toshihiko Fujii; Kaori Fujimoto-Ouchi; Masamichi Sugimoto; Shigehisa Nagahashi; Masahiro Aoki; Hiroshi Motegi; Eiichi Sasaki; Yasushi Yatabe
Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer
Catherine B. Meador; Hailing Jin; Elisa de Stanchina; Caroline A. Nebhan; Valentina Pirazzoli; Lu Wang; Pengcheng Lu; Huy Vuong; Katherine E. Hutchinson; Peilin Jia; Xi Chen; Rosana Eisenberg; Marc Ladanyi; Katerina Politi; Zhongming Zhao; Christine M. Lovly; Darren A.E. Cross; William Pao
Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Yuri Chikano; Takahiro Domoto; Takuya Furuta; Hemragul Sabit; Ayako Kitano-Tamura; Ilya V. Pyko; Takahisa Takino; Yoshimichi Sai; Yutaka Hayashi; Hiroshi Sato; Ken-ichi Miyamoto; Mitsutoshi Nakada; Toshinari Minamoto
Inhibition of the GTPase Rac1 Mediates the Antimigratory Effects of Metformin in Prostate Cancer Cells
Béatrice Dirat; Isabelle Ader; Muriel Golzio; Fabienne Massa; Amel Mettouchi; Kathiane Laurent; Frédéric Larbret; Bernard Malavaud; Mireille Cormont; Emmanuel Lemichez; Olivier Cuvillier; Jean François Tanti; Frédéric Bost
Companion Diagnostics and Cancer Biomarkers
Author Choice
Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
Abdullah A. Osman; Marcus M. Monroe; Marcus V. Ortega Alves; Ameeta A. Patel; Panagiotis Katsonis; Alison L. Fitzgerald; David M. Neskey; Mitchell J. Frederick; Sang Hyeok Woo; Carlos Caulin; Teng-Kuei Hsu; Thomas O. McDonald; Marek Kimmel; Raymond E. Meyn; Olivier Lichtarge; Jeffrey N. Myers
IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines
Fei Huang; Han Chang; Ann Greer; Stephen Hillerman; Karen A. Reeves; Warren Hurlburt; John Cogswell; Dharmesh Patel; Zhenhao Qi; Craig Fairchild; Rolf-Peter Ryseck; Tai W. Wong; Friedrich G. Finckenstein; Jeffrey Jackson; Joan M. Carboni
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.